Search Results for: 163

— Enrollment is Ongoing in Phase 2b Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C; Topline Data Readout Anticipated in 2H 2019 — — Conference Call Today, May 8, 2019, at 4:30 p.m. (ET) — ROCKVILLE, Md., May 8, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics that

— Conference Call Scheduled for Wednesday, February 27, 2019 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 19, 2019 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for

– Held End of Phase 2 Meeting with FDA and Received Guidance for Advancement to First Pivotal Trial for SYN-010, for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) – – Company Provides Update on Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase), for the Prevention of C. Difficile Infection (CDI) and

— Conference Call Scheduled for Wednesday, August 3, 2016 at 4:30 p.m. EDT — ROCKVILLE, Md., July 26, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, intends to release its operational highlights and financial results for the three and six

— The University of Texas at Austin Receives Grant from the Bill & Melinda Gates Foundation — ROCKVILLE, Md. and AUSTIN, Texas, Oct. 21, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, and its Pertussis academic collaborator, The University of

— Company’s SYN-010 Program to Reduce the Impact of Methane Gas in the Gut Currently in Phase 2 Clinical Trials — ROCKVILLE, Md., Oct. 20, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced that experimental results supporting the proposed

— Steady Progress in All Programs; Two Phase 2 Clinical Trials to Start in 2015 — — Conference Call Today, March 16, 2015, at 8:30 a.m. (ET) — ROCKVILLE, Md., March 16, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting

— Conference Call Scheduled for Monday, March 16, 2015, at 8:30 a.m. EDT — ROCKVILLE, Md., March 9, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced today that the Company intends to release its financial results for the

– Company Focused on Novel Anti-Infective Pipeline for the Prevention and Treatment of Serious Infections and Other Diseases – – Conference Call Scheduled for Monday, March 31, 2014, at 10:00 am EDT – ROCKVILLE, Md., March 25, 2014 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates